Denis Migliorini, MD is a Physician-Scientist and Associate Professor at the University of Geneva Faculty of Medicine since January 2026. An expert in neuro-onco-immunology, he treats patients with brain tumours and neurological complications of cancers. His research is dedicated to the design and validation of novel immunotherapies using chimeric antigen receptor T cells (CAR-T), which involves reprogramming patients' immune cells to fight tumours. To this end, he uses various gene transfer methods and combinatorial strategies for malignant gliomas and other hard-to-treat solid tumours. 

After studying medicine in Toulouse and Strasbourg, he specialised in medical oncology in Geneva (board certification in 2015) and in neuro-oncology. Holding a Advanced Studies Diploma (DA)S from UNIGE in clinical trial management, he became principal investigator of several early-phase studies testing various antitumour immunotherapy approaches, notably peptide vaccines for the treatment of glioblastoma. From 2016 to 2019, during a postdoctoral position at the University of Pennsylvania, he trained in synthetic biology and immune cell engineering, disciplines that enabled the development of CAR-T cell technology. In 2019, he was awarded the Swiss Bridge Foundation Prize in recognition of his work aimed at reducing the neurotoxic effects of cellular immunotherapies.
Upon his return to Switzerland, he was appointed Assistant Professor in 2020, ISREC Foundation Chair in Brain Tumour Immunology at the Department of Medicine and the Translational Research Centre in Onco-Haematology (CRTOH) of the UNIGE Faculty of Medicine, and member of the Swiss Cancer Centre – Léman. He was appointed Associate Professor in January 2026.His research lab at the Agora Centre for cancer research in Lausanne has a strong translational focus to ensure that his therapeutic approaches are rapidly accessible patients. Thus, the CAR-T therapies developed in his laboratory will be evaluated in patients with glioblastoma in an early-phase study from early 2027 onwards. 

At HUG, he is the head of the neuro-oncology clinic and tumour board, and coordinator of the brain tumour biobank. He is an active member of the Swiss and European Association of Neuro-Oncology (Swiss NOS, EANO) and serves on the editorial board of the leading journal in his field - Neuro-Oncology.